StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

KPIs

Operating metrics that drive Gilead Sciences's business · fiscal year ends Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Add to chartMetric
Q2 2026
2026-06-30
Q1 2026
2026-03-31
Q4 2025
2025-12-31
Q3 2025
2025-09-30
Q2 2025
2025-06-30
Q1 2025
2025-03-31
Q4 2024
2024-12-31
Q3 2024
2024-09-30
Q2 2024
2024-06-30
Q1 2024
2024-03-31
Q4 2023
2023-12-31
Q3 2023
2023-09-30
Total revenues ($M)($M)3
7,8036,9607,9257,7697,0826,6677,5697,5456,9546,6867,1147,051
Total revenues YoY growth (%)(%)
10.0%4.0%5.0%3.0%2.0%6.0%7.0%5.0%5.0%-4.0%
Total product sales ($M)($M)5
7,6276,9467,9027,3457,0546,6137,5367,5156,9126,6477,0706,994
Total product sales excluding Veklury (Base business, $M)($M)1
7,6046,8027,6917,0686,9346,3117,1986,8236,6986,0926,3506,358
Product sales ex-Veklury YoY growth (%)(%)
10.0%8.0%7.0%4.0%4.0%4.0%13.0%7.0%6.0%6.0%-24.0%5.0%
Total product sales — U.S. ($M)($M)
5,6014,9265,8735,2745,0384,6315,5505,4334,9164,6095,1814,985
Total product sales — Europe ($M)($M)
1,1551,1371,2221,1441,1781,0731,1601,1541,1181,1441,1281,017
Total product sales — Rest of World ($M)($M)
872883809928838909826928878894762992
Total product sales YoY growth (%)(%)
8.0%5.0%5.0%-2.0%2.0%-1.0%7.0%7.0%5.0%5.0%-4.0%
Royalty, contract and other revenues ($M)($M)4
17614224242754333041394456
Royalty, contract and other revenues — U.S. ($M)($M)
2037133716172523532
Royalty, contract and other revenues — Europe ($M)($M)
1698144111011151315153723
Royalty, contract and other revenues — Rest of World ($M)($M)
464546211131
Royalty, contract and other revenues YoY growth (%)(%)
-75.0%-35.0%-34.0%37.0%-26.0%-46.0%18.0%-15.0%-21.0%-13.0%
Consolidated revenues — United States ($M)($M)2
5,6034,9265,8765,2815,0514,6685,5675,4504,9414,6335,1855,017
Consolidated revenues — Europe ($M)($M)
1,3241,1441,2361,5551,1891,0841,1751,1671,1331,1591,1641,040
Consolidated revenues — Rest of World / Other International ($M)($M)
876889813933842915826929879894765993
Total HIV Franchise Product Sales ($M)($M)13
5,6935,0305,8005,2775,0884,5875,4525,0734,7454,3424,6934,667
Total HIV Franchise Product Sales — U.S. sales ($M)($M)
4,6594,0044,8454,2994,0963,6644,5324,1613,8213,4053,8993,807
Total HIV Franchise Product Sales — Europe sales ($M)($M)
640607623592624553602570571596534519
Total HIV Franchise Product Sales — Rest of World sales ($M)($M)
393419332386368370317342353342261341
Total HIV Franchise Product Sales — Worldwide YoY growth (%)(%)
12.0%10.0%6.0%4.0%7.0%6.0%16.0%9.0%3.0%4.0%-2.0%4.0%
Biktarvy (bictegravir / FTC / TAF) ($M)($M)3
3,7723,3613,9683,6863,5303,1503,7743,4723,2322,9463,1093,085
Biktarvy (bictegravir / FTC / TAF) — U.S. sales ($M)($M)
2,9812,5733,2552,9402,7992,4743,1292,8262,5852,3152,5882,504
Biktarvy (bictegravir / FTC / TAF) — Europe sales ($M)($M)
468437445427429375399375370365333313
Biktarvy (bictegravir / FTC / TAF) — Rest of World sales ($M)($M)
323352268320302301246272277265188268
Descovy (FTC / TAF — HIV treatment & PrEP) ($M)($M)3
967807819701653586617586485426510511
Descovy (FTC / TAF — HIV treatment & PrEP) — U.S. sales ($M)($M)
921761768652601538563534434371457460
Descovy (FTC / TAF — HIV treatment & PrEP) — Europe sales ($M)($M)
232326232421252425262525
Descovy (FTC / TAF — HIV treatment & PrEP) — Rest of World sales ($M)($M)
232324252827282826292826
Genvoya (elvitegravir / cobicistat / FTC / TAF) ($M)($M)3
289264380377377364470449440403516503
Genvoya (elvitegravir / cobicistat / FTC / TAF) — U.S. sales ($M)($M)
236215331323322305410384372332447433
Genvoya (elvitegravir / cobicistat / FTC / TAF) — Europe sales ($M)($M)
373334344040424445494847
Genvoya (elvitegravir / cobicistat / FTC / TAF) — Rest of World sales ($M)($M)
161615191619182123212223
Odefsey (FTC / rilpivirine / TAF) ($M)($M)3
239221310277298281336326315310339343
Odefsey (FTC / rilpivirine / TAF) — U.S. sales ($M)($M)
171153239206221215252248233223258257
Odefsey (FTC / rilpivirine / TAF) — Europe sales ($M)($M)
585962616657736972767174
Odefsey (FTC / rilpivirine / TAF) — Rest of World sales ($M)($M)
1091010111011910111111
Symtuza revenue share (darunavir / cobicistat / FTC / TAF) ($M)($M)3
138138133124124114144139168141139131
Symtuza revenue share (darunavir / cobicistat / FTC / TAF) — U.S. sales ($M)($M)
1051079895888211210313110410496
Symtuza revenue share (darunavir / cobicistat / FTC / TAF) — Europe sales ($M)($M)
302832263329293334333232
Symtuza revenue share (darunavir / cobicistat / FTC / TAF) — Rest of World sales ($M)($M)
333333333333
Other HIV products (incl. Sunlenca & Yeztugo prior to Q1 2026) ($M)($M)3
567319011292911121001051178094
Other HIV products (incl. Sunlenca & Yeztugo prior to Q1 2026) — U.S. sales ($M)($M)
2336154825050676565604656
Other HIV products (incl. Sunlenca & Yeztugo prior to Q1 2026) — Europe sales ($M)($M)
242724223331332625452528
Other HIV products (incl. Sunlenca & Yeztugo prior to Q1 2026) — Rest of World sales ($M)($M)
109129910129151299
Truvada (FTC / TDF — legacy standalone breakout) ($M)($M)3
1722
Truvada (FTC / TDF — legacy standalone breakout) — U.S. sales ($M)($M)
1115
Truvada (FTC / TDF — legacy standalone breakout) — Europe sales ($M)($M)
33
Truvada (FTC / TDF — legacy standalone breakout) — Rest of World sales ($M)($M)
34
Stribild (elvitegravir / cobicistat / FTC / TDF — legacy breakout) ($M)($M)3
2225
Stribild (elvitegravir / cobicistat / FTC / TDF — legacy breakout) — U.S. sales ($M)($M)
1518
Stribild (elvitegravir / cobicistat / FTC / TDF — legacy breakout) — Europe sales ($M)($M)
55
Stribild (elvitegravir / cobicistat / FTC / TDF — legacy breakout) — Rest of World sales ($M)($M)
22
Complera / Eviplera (FTC / rilpivirine / TDF — legacy breakout) ($M)($M)3
2534
Complera / Eviplera (FTC / rilpivirine / TDF — legacy breakout) — U.S. sales ($M)($M)
713
Complera / Eviplera (FTC / rilpivirine / TDF — legacy breakout) — Europe sales ($M)($M)
1518
Complera / Eviplera (FTC / rilpivirine / TDF — legacy breakout) — Rest of World sales ($M)($M)
33
Total Liver Disease Franchise Product Sales ($M)($M)9
877767845819795758719733832737691706
Total Liver Disease Franchise Product Sales — U.S. sales ($M)($M)
433362457414413335391393431385370376
Total Liver Disease Franchise Product Sales — Europe sales ($M)($M)
193170175158170168134132142137121119
Total Liver Disease Franchise Product Sales — Rest of World sales ($M)($M)
251235213247211256194207259215200211
Total Liver Disease Franchise Product Sales — Worldwide YoY growth (%)(%)
10.0%1.0%17.0%12.0%-4.0%3.0%4.0%4.0%17.0%9.0%-1.0%-10.0%
Sofosbuvir / Velpatasvir (Epclusa & authorized generic — HCV) ($M)($M)3
303283276309342346330385476405378377
Sofosbuvir / Velpatasvir (Epclusa & authorized generic — HCV) — U.S. sales ($M)($M)
142141139146184166185222267248216215
Sofosbuvir / Velpatasvir (Epclusa & authorized generic — HCV) — Europe sales ($M)($M)
816065658180696784797376
Sofosbuvir / Velpatasvir (Epclusa & authorized generic — HCV) — Rest of World sales ($M)($M)
8082719776997596126788985
Vemlidy (tenofovir alafenamide — HBV) ($M)($M)3
289237287280252252260232243225217228
Vemlidy (tenofovir alafenamide — HBV) — U.S. sales ($M)($M)
1249114913612210014812611795115112
Vemlidy (tenofovir alafenamide — HBV) — Europe sales ($M)($M)
13131312131211111111109
Vemlidy (tenofovir alafenamide — HBV) — Rest of World sales ($M)($M)
1521321251321171401009511511992106
Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) ($M)($M)3
11811428123112312113011611310796102
Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — U.S. sales ($M)($M)
20151691323328584547423949
Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Europe sales ($M)($M)
797897817276545447473833
Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Rest of World sales ($M)($M)
192116171917181719191920
Total HCV Franchise (legacy sub-franchise breakout) ($M)($M)5
432438
Total HCV Franchise (legacy sub-franchise breakout) — U.S. sales ($M)($M)
251260
Total HCV Franchise (legacy sub-franchise breakout) — Europe sales ($M)($M)
8485
Total HCV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M)($M)
9793
Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) ($M)($M)3
1623
Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — U.S. sales ($M)($M)
1017
Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — Europe sales ($M)($M)
12
Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — Rest of World sales ($M)($M)
54
Other HCV (Sovaldi — legacy breakout) ($M)($M)3
3738
Other HCV (Sovaldi — legacy breakout) — U.S. sales ($M)($M)
2428
Other HCV (Sovaldi — legacy breakout) — Europe sales ($M)($M)
107
Other HCV (Sovaldi — legacy breakout) — Rest of World sales ($M)($M)
23
Total HBV / HDV Franchise (legacy sub-franchise breakout) ($M)($M)5
259269
Total HBV / HDV Franchise (legacy sub-franchise breakout) — U.S. sales ($M)($M)
119116
Total HBV / HDV Franchise (legacy sub-franchise breakout) — Europe sales ($M)($M)
3734
Total HBV / HDV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M)($M)
103119
Viread (tenofovir disoproxil fumarate — legacy breakout) ($M)($M)3
2121
Viread (tenofovir disoproxil fumarate — legacy breakout) — U.S. sales ($M)($M)
44
Viread (tenofovir disoproxil fumarate — legacy breakout) — Europe sales ($M)($M)
55
Viread (tenofovir disoproxil fumarate — legacy breakout) — Rest of World sales ($M)($M)
1212
Other HBV / HDV (Hepcludex / Hepsera — legacy breakout) ($M)($M)3
2120
Other HBV / HDV (Hepcludex / Hepsera — legacy breakout) — U.S. sales ($M)($M)
00
Other HBV / HDV (Hepcludex / Hepsera — legacy breakout) — Europe sales ($M)($M)
2219
Other HBV / HDV (Hepcludex / Hepsera — legacy breakout) — Rest of World sales ($M)($M)
00
Veklury (remdesivir — COVID-19 antiviral) ($M)($M)4
23144211277121302338692214555719636
Veklury (remdesivir — COVID-19 antiviral) — U.S. sales ($M)($M)
14112801405119910839376315365258
Veklury (remdesivir — COVID-19 antiviral) — Europe sales ($M)($M)
214674319228081537018165
Veklury (remdesivir — COVID-19 antiviral) — Rest of World sales ($M)($M)
7186593508215021985169175313
Veklury (remdesivir — COVID-19 antiviral) — Worldwide YoY growth (%)(%)
-81.0%-52.0%-37.0%-60.0%-44.0%-45.0%-53.0%9.0%-16.0%-3.0%-28.0%-31.0%
Total Oncology Franchise Product Sales ($M)($M)6
873810841788849757843816841789765769
Total Oncology Franchise Product Sales — U.S. sales ($M)($M)
468403434384427381460433474431479462
Total Oncology Franchise Product Sales — Europe sales ($M)($M)
265278281275291255270291275262215243
Total Oncology Franchise Product Sales — Rest of World sales ($M)($M)
1401291271291311211139292967165
Total Oncology Franchise Product Sales — Worldwide YoY growth (%)(%)
3.0%7.0%4.0%-3.0%1.0%-4.0%10.0%6.0%15.0%18.0%24.0%33.0%
Total Kite Cell Therapy Product Sales ($M)($M)5
417407458432485464488485521480467486
Total Kite Cell Therapy Product Sales — U.S. sales ($M)($M)
161150182163203200213208250225253261
Total Kite Cell Therapy Product Sales — Europe sales ($M)($M)
173183193186196180193211206195167181
Total Kite Cell Therapy Product Sales — Rest of World sales ($M)($M)
837482838684826666604745
Yescarta (axicabtagene ciloleucel — LBCL / FL CAR T) ($M)($M)3
346332368349393386389387414380368391
Yescarta (axicabtagene ciloleucel — LBCL / FL CAR T) — U.S. sales ($M)($M)
132120151123162160160145186170187197
Yescarta (axicabtagene ciloleucel — LBCL / FL CAR T) — Europe sales ($M)($M)
139146143151154149157182169158139154
Yescarta (axicabtagene ciloleucel — LBCL / FL CAR T) — Rest of World sales ($M)($M)
756775757777726058524140
Tecartus (brexucabtagene autoleucel — MCL / ALL CAR T) ($M)($M)3
70759083927898981071009896
Tecartus (brexucabtagene autoleucel — MCL / ALL CAR T) — U.S. sales ($M)($M)
293031404140536363556664
Tecartus (brexucabtagene autoleucel — MCL / ALL CAR T) — Europe sales ($M)($M)
343751354131362937362727
Tecartus (brexucabtagene autoleucel — MCL / ALL CAR T) — Rest of World sales ($M)($M)
887898967844
Trodelvy (sacituzumab govitecan-hziy — TROP-2 ADC) ($M)($M)3
457402384357364293355332320309299283
Trodelvy (sacituzumab govitecan-hziy — TROP-2 ADC) — U.S. sales ($M)($M)
307253251221224181247226224206226201
Trodelvy (sacituzumab govitecan-hziy — TROP-2 ADC) — Europe sales ($M)($M)
929588899675778069684862
Trodelvy (sacituzumab govitecan-hziy — TROP-2 ADC) — Rest of World sales ($M)($M)
575445474437312626362421
Total Other Products Sales ($M)($M)6
161196205184202209184201280224201216
Total Other Products Sales — U.S. sales ($M)($M)
2646573652525853115736882
Total Other Products Sales — Europe sales ($M)($M)
556775767376748077797772
Total Other Products Sales — Rest of World sales ($M)($M)
808372727781526888715662
AmBisome (liposomal amphotericin B — systemic antifungal) ($M)($M)3
110138118123129139109130151144111115
AmBisome (liposomal amphotericin B — systemic antifungal) — U.S. sales ($M)($M)
475275761714412
AmBisome (liposomal amphotericin B — systemic antifungal) — Europe sales ($M)($M)
475966696567667169706863
AmBisome (liposomal amphotericin B — systemic antifungal) — Rest of World sales ($M)($M)
597246525666365265603939
Other Products (Cayston, Jyseleca, Letairis, Zydelig) ($M)($M)4
51588661737075711308090101
Other Products (Cayston, Jyseleca, Letairis, Zydelig) — U.S. sales ($M)($M)
223952344447524798596469
Other Products (Cayston, Jyseleca, Letairis, Zydelig) — Europe sales ($M)($M)
889789888999
Other Products (Cayston, Jyseleca, Letairis, Zydelig) — Rest of World sales ($M)($M)
211126202114161624121723
Other Products (Cayston, Jyseleca, Letairis, Zydelig) — Worldwide YoY growth (%)(%)
-20.0%-6.0%11.0%-8.0%-28.0%-7.0%-8.0%-7.0%15.0%13.0%-20.0%8.0%
Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) ($M)($M)3
3636
Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) — U.S. sales ($M)($M)
3636
Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) — Europe sales ($M)($M)
00
Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) — Rest of World sales ($M)($M)
00
Accrued rebates and chargebacks liability (Balance Sheet, $M)($M)
4,2334,1184,3374,9314,2154,1853,8924,1133,9234,2633,8023,714
GAAP Research and development (R&D) expenses ($M)($M)3
1,7641,3721,5841,3461,4911,3791,6411,3951,3511,5201,4081,457
R&D by cost type — Personnel, infrastructure and other support costs ($M)($M)
1,146861911807855854954808830963823776
R&D by cost type — Clinical studies and outside services / other costs ($M)($M)
618510673539636524687587520557585681
Non-GAAP Research and development expenses ($M)($M)1
1,7641,3721,5841,3461,4911,3791,6411,3951,3511,5201,4081,457
Non-GAAP R&D expenses as % of total revenues (%)(%)
22.6%19.7%20.0%17.3%21.1%20.7%21.7%18.5%19.4%22.7%19.8%20.7%
Acquired in-process research and development (IPR&D) expenses ($M)($M)1
11,18310753917061253-11505384,13134791
In-process research and development (IPR&D) impairment charges ($M)($M)
12,04310753917061253-11505384,13134791
Equity method & fair value option biotech investments carrying value ($M)($M)3
295308393393369359386382376359340
Equity method investment in Arcus Biosciences, Inc. — Fair value carrying amount ($M)($M)
969679749427448266
Equity method investment in Galapagos NV / Lakefront Biotherapeutics NV — Fair value carrying amount ($M)($M)
500504551570462571
Other equity method investments (incl. Assembly Biosciences) — Fair value carrying amount ($M)($M)
17115518314353
Strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M)($M)7
337116882371110-4932
Arcus revenue from Gilead — Other collaboration revenue ($M)($M)
2554688871110910
Arcus total other collaboration revenue ($M)($M)
2554688871110910
Arcus revenue from Gilead — License & development services (legacy axis, $M)($M)
81015220
Arcus Biosciences — Total operating expenses ($M)($M)2
137151147168168150129153145161122112
Arcus Biosciences — Research and development (R&D) expense ($M)($M)
1131221211411391221011231151099382
Arcus Biosciences — General and administrative (G&A) expense ($M)($M)
242926272928283030322930
Arcus Biosciences — Operating income (loss) ($M)($M)
-96-134-114-142-8-122-103-105-106-16-91-80
Arcus Biosciences — Net income (loss) ($M)($M)2
-91-128-106-1350-112-94-92-93-4-81-71
Arcus Biosciences — Diluted EPS ($/sh)($)
-0.72-1.02-1.270-1.14-1-1.02-0.05-0.94
Arcus Biosciences — Diluted weighted-average shares (M shares)
1261254107107981919186075
Arcus Biosciences — Total assets ($M)($M)6
9249971,1399741,0751,1561,1501,2521,1861,2931,0951,191
Arcus Biosciences — Cash and cash equivalents ($M)($M)
150201222238248192150201156185127184
Arcus Biosciences — Marketable securities, current ($M)($M)
552621759593663805828888813810632615
Arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M)($M)
36311111515201628353852
Arcus Biosciences — Deferred collaboration revenue, current ($M)($M)
1934355271728510511312491103
Arcus Biosciences — Deferred collaboration revenue, noncurrent ($M)($M)
3745435360219234289214242307326
Arcus Biosciences — Total current liabilities ($M)($M)
198209231235210192226215199204184200
Non-GAAP product gross margin (%)(%)4
79.3%79.2%79.5%78.6%78.7%76.7%79.0%79.1%77.7%76.6%70.4%77.6%
GAAP product gross margin (%)(%)
79.3%79.2%79.5%78.6%78.7%76.7%79.0%79.1%77.7%76.6%70.4%77.6%
Non-GAAP cost of goods sold ($M)($M)
1,5791,4451,6231,5691,5011,5401,5811,5741,5441,5522,0901,565
GAAP cost of goods sold ($M)($M)
1,5791,4451,6231,5691,5011,5401,5811,5741,5441,5522,0901,565
Non-GAAP COGS adjustments (Acquired intangible amortization & step-up, $M)($M)
5795765795775795795795795795791,110581
Non-GAAP operating margin (%)(%)3
-133.2%37.2%25.0%42.8%34.9%33.6%32.4%11.8%38.0%-64.6%22.7%37.2%
GAAP operating margin (%)(%)
-133.2%37.2%25.0%42.8%34.9%33.6%32.4%11.8%38.0%-64.6%22.7%37.2%
Non-GAAP operating income (loss) ($M)($M)
-10,3942,5861,9843,9212,4742,2372,4513,2583,265-4,3221,6123,224
Non-GAAP selling, general and administrative (SG&A) expenses ($M)($M)2
1,9211,4511,7941,3571,3651,2581,9061,4331,3771,3751,6081,315
Non-GAAP SG&A expenses as % of total revenues (%)(%)
24.6%20.9%22.6%17.5%19.3%18.9%25.2%19.0%19.8%20.6%22.6%18.6%
Non-GAAP SG&A adjustments ($M)($M)
400881065736542826801117
Non-GAAP net income (loss) attributable to Gilead ($M)($M)4
-10,4962,0212,1833,0951,9601,3151,7832,5312,519-4,1701,4172,879
Non-GAAP diluted earnings (loss) per share ($/sh)($)
-8.451.611.862.471.561.041.902.022.01-1.321.722.29
Non-GAAP effective tax rate (%)(%)
-2.4%21.7%-5.0%16.2%19.3%20.2%17.8%-31.1%21.4%7.0%14.3%6.3%
GAAP effective tax rate (%)(%)
-2.4%21.7%-5.0%16.2%19.3%20.2%17.8%-31.1%21.4%7.0%14.3%6.3%
Total non-GAAP adjustments before income taxes ($M)($M)6
2,7225398521126751,0827892,1131,0123,219938770
Total non-GAAP adjustments to costs and expenses ($M)($M)
3,0656811,1045948176566632,3706203,2051,127602
Non-GAAP R&D adjustments ($M)($M)
3351719124140291316117-444
Non-GAAP other income (expense) adjustments (equity securities fair value, $M)($M)
-343-142-252-483-142426126-25839214-189168
Income tax effect of non-GAAP adjustments ($M)($M)
-574-58-252-79-162-154-152-521-168-732-218-129
Discrete and related tax charges (benefits) ($M)($M)
44-46454-11-48-4229314-60-39-12-58
Total non-GAAP adjustments after tax ($M)($M)
2,105528146435609706071,2789052,526732699
Non-GAAP Free cash flow (Form 8-K Selected Cash Flow Information, $M)($M)2
3,4322,4273,1213,9627201,6532,8284,1691,1952,1141,9541,633
Operating cash flow (Form 8-K Selected Cash Flow Information, $M)($M)
3,5732,5443,3264,1098271,7572,9754,3091,3252,2192,1681,756
Capital expenditures (Form 8-K Selected Cash Flow Information, $M)($M)
140117205147107104147140130105214122
Total inventories (Current + Noncurrent, $M)($M)5
4,2984,3394,3684,3873,9133,7783,5893,4353,3883,3633,3663,202
Inventories — Raw materials ($M)($M)
1,4151,3571,4141,3961,2711,1961,2951,3321,2591,2371,2461,266
Inventories — Work in process ($M)($M)
1,1631,2761,3061,3411,0391,076847684803778847614
Inventories — Finished goods ($M)($M)
1,7191,7061,6471,6501,6031,5061,4471,4191,3261,3481,2721,323
Inventories — Current portion (Balance Sheet, $M)($M)
1,9531,9141,7741,7851,8251,7591,7101,8692,0261,8531,7871,663
Inventories — Noncurrent portion (included in Other long-term assets, $M)($M)
2,3452,4242,5942,6022,0872,0181,8791,5661,3621,5101,5781,539
Property, plant and equipment, net ($M)($M)2
5,8335,6385,6065,5005,4595,4215,4145,3915,3465,3215,3175,572
Property, plant and equipment, gross ($M)($M)
8,7078,4228,3028,1938,0807,9637,8847,766
Accumulated depreciation ($M)($M)
2,8742,7842,6962,6932,6212,5422,4702,449
Intangible assets, net ($M)($M)3
14,03216,38216,97817,97018,56619,35519,94820,54622,83223,42826,45427,152
Goodwill ($M)($M)
8,3148,3148,3148,3148,3148,3148,3148,3148,3148,3148,3148,314
Finite-lived intangible assets, net ($M)($M)7
14,03214,08214,67815,27015,86616,46517,05817,65618,19218,78819,38420,032
Finite-lived intangible assets, gross ($M)($M)
32,41331,86331,88831,88431,88431,88431,87931,87931,81931,81931,81931,894
Finite-lived intangible assets — Accumulated amortization ($M)($M)
18,38217,78217,21116,61416,01915,42114,82214,22413,62813,03212,43611,863
Trodelvy (sacituzumab govitecan) intangible asset — Net carrying value ($M)($M)2
7,0267,2967,5667,8368,1078,3778,6478,9179,1879,4589,7289,998
Trodelvy intangible asset — Gross ($M)($M)
11,73011,73011,73011,73011,73011,73011,73011,73011,73011,73011,73011,730
Trodelvy intangible asset — Accumulated amortization ($M)($M)
4,7044,4344,1643,8943,6233,3533,0832,8132,5432,2722,0021,732
Sofosbuvir (Epclusa / Harvoni / Vosevi) intangible asset — Net carrying value ($M)($M)2
1,9232,0972,2722,4472,6222,7972,9713,1463,3213,4963,6703,845
Sofosbuvir intangible asset — Gross ($M)($M)
10,72010,72010,72010,72010,72010,72010,72010,72010,72010,72010,72010,720
Sofosbuvir intangible asset — Accumulated amortization ($M)($M)
8,7978,6238,4488,2738,0987,9237,7497,5747,3997,2247,0506,875
Yescarta (axicabtagene ciloleucel) intangible asset — Net carrying value ($M)($M)2
3,7803,8813,9834,0844,1864,2884,3894,4914,5934,6944,7964,897
Yescarta intangible asset — Gross ($M)($M)
7,1107,1107,1107,1107,1107,1107,1107,1107,1107,1107,1107,110
Yescarta intangible asset — Accumulated amortization ($M)($M)
3,3303,2293,1273,0262,9242,8222,7212,6192,5172,4162,3142,213
Hepcludex (bulevirtide) intangible asset — Net carrying value ($M)($M)2
933408430451473494516537559580602623
Hepcludex intangible asset — Gross ($M)($M)
1,395845845845845845845845845845845845
Hepcludex intangible asset — Accumulated amortization ($M)($M)
462437415394372351329308286265243222
Other finite-lived intangible assets — Net carrying value ($M)($M)2
372400428451479510535565533560588668
Other finite-lived intangible assets — Gross ($M)($M)
1,4581,4581,4831,4791,4791,4791,4741,4741,4141,4141,4141,489
Other finite-lived intangible assets — Accumulated amortization ($M)($M)
1,0871,0591,0561,0281,001971940911883855827822
Indefinite-lived IPR&D intangible assets ($M)($M)1
02,3002,3002,7002,7002,8902,8902,8904,6404,6407,070
Indefinite-lived IPR&D — Trodelvy NSCLC (impaired in FY2024, $M)($M)
1,7501,7501,7501,7501,8001,7501,8005,900
Level 3 contingent consideration liabilities ($M)($M)1
60275278274271216206222208222228275
Contingent consideration liability — MYR GmbH / Hepcludex ($M)($M)
60275278274271216206222208222228275
Litigation accrual reserve (Antitrust, patent & product liability, $M)($M)
0000022024200
Restructuring expenses — Total ($M)($M)3
17403714137476282163
Restructuring expenses — Research and development ($M)($M)
141686383051350
Restructuring expenses — Selling, general and administrative ($M)($M)
251757364623813
Accrued restructuring liability ($M)($M)
607361529213893
Long-term debt, noncurrent carrying value ($M)($M)3
23,83220,86122,12922,13522,14022,14624,89621,43721,54021,52723,18923,189
Current portion of long-term debt and senior notes ($M)($M)
2,4141,3132,8072,8062,8062,8061,8151,8121,8093,6671,7981,793
Total debt carrying value ($M)($M)
26,24622,17424,93724,94124,94624,95226,71023,24923,34925,19324,98724,982
Total long-term debt fair value ($M)($M)
22,26219,17822,34222,39821,98121,88623,33520,93119,84121,93022,56720,900
Cash dividends declared per share ($/sh)($)3
0.820.820.790.790.790.770.770.770.75
Common stock repurchases — Cash paid ($M)($M)
355419230435527730350300100400150300
Common stock repurchases — Value retired ($M)($M)
355419230435527730350300100400150300
Common stock repurchases — Shares repurchased (M shares)
332457342524
Total stock-based compensation (SBC) expense ($M)($M)
231218230230225209222216210187201202
Income tax expense (benefit) ($M)($M)
242559-105589468334385-297438-315237146
Global employees headcount (people)1
Deferred compensation plan rabbi trust assets & liabilities ($M)($M)
458405406401374340343343327318284259
U.S. PPI: Pharmaceutical Preparation Manufacturing (Index Dec 2009=100)1
U.S. PCE: Pharmaceutical and Other Medical Products ($B SAAR)
3,790.303,699.903,667.003,614.803,529.803,464.703,417.803,358.203,288.203,244.403,159.403,079.00
Income Statement — Total revenues ($M)($M)10
7,8036,9607,9257,7697,0826,6677,5697,5456,9546,6867,1147,051
Cost of goods sold ($M)($M)
1,5791,4451,6241,5691,5011,5401,5811,5741,5441,5522,0901,565
Research and development expenses ($M)($M)
1,7641,3721,5841,3461,4911,3791,6411,3951,3511,5201,4081,457
Selling, general and administrative expenses ($M)($M)
1,9211,4511,7941,3571,3651,2581,9071,4331,3771,3751,6081,315
Operating income (loss) ($M)($M)
-10,3942,5861,9843,3272,4742,2372,4528882,644-4,3221,6122,623
Interest expense ($M)($M)
247240255256254260249238237254252232
Income (loss) before income taxes ($M)($M)
-10,2542,5802,0783,6412,4291,6492,1679562,053-4,4861,6532,318
Income tax expense (benefit) ($M)($M)
242559-105589468334385-297438-315237146
Net income (loss) attributable to Gilead ($M)($M)
-10,4962,0212,1833,0521,9601,3151,7831,2531,614-4,1701,4292,180
Diluted earnings (loss) per share ($/sh)($)
-8.451.612.431.561.0411.29-3.341.73
Diluted weighted-average shares (M shares)
1,2431,2541,2541,2551,2591,2541,2511,2471,257
Balance Sheet — Total assets ($M)($M)10
49,36256,27859,02358,53355,72156,43458,99554,52553,57956,29262,12562,373
Accounts receivable, net ($M)($M)
5,0554,7414,9135,0954,7814,3884,4204,5874,6634,6694,6604,790
Inventories ($M)($M)
1,9531,9141,7741,7851,8251,7591,7101,8692,0261,8531,7871,663
Total current assets ($M)($M)
13,94518,64118,34217,87414,71816,90119,17314,77912,31714,04116,08515,980
Property, plant and equipment, net ($M)($M)
5,8335,6385,6065,5005,4595,4215,4145,3915,3465,3215,3175,572
Goodwill ($M)($M)
8,3148,3148,3148,3148,3148,3148,3148,3148,3148,3148,3148,314
Intangible assets, net ($M)($M)
14,03216,38216,97817,97018,56619,35519,94820,54622,83223,42826,45427,152
Total current liabilities ($M)($M)
11,0209,47611,81312,29811,18912,34412,00411,72510,78113,01511,28011,945
Long-term debt, noncurrent ($M)($M)
23,83220,86122,12922,13522,14022,14624,89621,43721,54021,52723,18923,189
Retained earnings ($M)($M)
2,20014,13113,73012,82511,32510,93111,49711,07311,16510,65616,30416,002
Total stockholders' equity ($M)($M)
11,74423,43122,61821,45619,59019,07819,24618,39018,19717,45522,74922,242
Cash Flow Statement — Operating cash flow ($M)($M)3
3,5732,5443,3274,1088271,7572,9754,3091,3252,2192,1691,755
Capital expenditures ($M)($M)
140117205147107104147141130105215122
Cash dividends paid ($M)($M)
1,0291,0409941,0059941,010973983972990943953
Repurchases of common stock ($M)($M)
355419230435527730350300100400150300

20 metrics have no data in the last 12 quarters — .

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Fiscal calendar: Gilead Sciences, Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Gilead operates as a single global biopharmaceutical operating segment (Note 16), so commercial performance is tracked across Therapeutic Area franchises (HIV, Liver Disease, Veklury, Oncology / Cell Therapy & Trodelvy, Other Products) and 2-dimensional Brand × Geography (Worldwide, U.S., Europe, Rest of World) product sales.
  • Core commercial, GTN & R&D KPIs (Groups 1–7) cover: (1) Consolidated Revenues ($7,805M in Q2 2026 / $29,440M in FY25), Total Product Sales ($7,629M in Q2 2026 / $28,913M in FY25 across U.S. $5,574M, Europe $1,226M, Rest of World $829M in Q2 2026), Base Business Product Sales excluding Veklury ($7,606M in Q2 2026, +11% YoY / $28,001M in FY25), Royalty/Contract revenues ($176M in Q2 2026 / $527M in FY25), and foreign currency sales share (25% in Q2 2026 / 26% in FY25); (2) HIV Franchise ($5,747M in Q2 2026, +12% YoY / $20,785M in FY25: Biktarvy $3,772M, Descovy $967M, Genvoya $392M, Odefsey $291M, Symtuza revenue share $145M, Yeztugo twice-yearly PrEP injectable $169M in Q2 2026, plus legacy Truvada/Stribild/Complera/Atripla, Biktarvy U.S. HIV treatment share & U.S. PrEP market volume growth); (3) Liver Disease Franchise ($877M in Q2 2026, +10% YoY / $3,172M in FY25: Sofosbuvir/Velpatasvir Epclusa $351M, Vemlidy $276M, Livdelzi PBC launch $167M, Other Liver $83M, plus historical HCV/HBV/HDV breakouts) and Veklury ($23M in Q2 2026 / $911M in FY25); (4) Oncology Franchise ($874M in Q2 2026, +4% YoY / $3,294M in FY25: Kite Cell Therapy $417M [Yescarta $344M, Tecartus $73M] and Trodelvy ADC $457M) & Other Products ($107M in Q2 2026: AmBisome $66M, Other $41M); (5) Gross-to-Net (GTN) deductions ($19,953M or 41% of gross product sales in FY25), 13-year Rebates & Chargebacks rollforward ($5,181M ending balance in FY25; $6,089M accrued at Q2 2026), and Top 3 U.S. wholesaler concentration (McKesson 37%, Cencora 30%, Cardinal Health 12% of FY25 revenues); (6) R&D Cost Structure ($1,764M GAAP R&D in Q2 2026 split between Personnel/Infrastructure $1,146M and Clinical Studies $618M; $11,183M Acquired IPR&D in Q2 2026 from Arcellx/Tubulis/Ouro acquisitions), biotech ownership stakes (Arcus 32.0%, Galapagos 25.1%, Assembly 29.5%), and standalone financial & Gilead-collaboration KPIs of listed oncology affiliate Arcus Biosciences, Inc. (NYSE: RCUS, CIK 0001724521); and (7) GAAP vs. Non-GAAP Reconciliations (86.9% Non-GAAP gross margin in Q2 2026; $8.15 Non-GAAP diluted EPS in FY25; $3,432M Free Cash Flow in Q2 2026).
  • Groups 8–12 cover: (8) Inventories by production stage ($2,521M total at Q2 2026: Raw Materials $1,226M, WIP $656M, Finished Goods $639M), PP&E by geography ($6,073M net at Q2 2026), Goodwill ($8,763M) & Drug Intangible Assets ($16,442M net at Q2 2026: Trodelvy $9,779M, Sofosbuvir $1,512M, Yescarta $2,665M, Hepcludex $753M, Bulevirtide IPR&D $300M, plus 5-year future amortization schedule), and Operating Leases ($1,552M ROU assets at Q2 2026); (9) Level 3 Contingent Consideration ($425M at Q2 2026), Litigation Accrual Reserve ($153M at Q2 2026 & TDF/TAF product liability plaintiff counts), and Restructuring; (10) Debt & 5-Year Maturity Schedule ($22,201M noncurrent long-term debt at Q2 2026), Capital Return ($1,030M dividends / $0.82 per share and $376M buybacks in Q2 2026), Stock-Based Compensation by P&L line & award type ($1,039M in FY25), and Income Taxes (DTA/DTL breakdown & UTB rollforward $1,128M at FY25); (11) Global Workforce (~17,000 employees, $200M 401(k) match, $406M deferred compensation plan in FY25), CEO Pay Ratio (119:1 / $238,979 median employee in FY25), Workplace Safety (62 recordable injuries / 0.36 TRIR per 200K hours in FY25), and 9-year Environmental Sustainability inventory (50,391 mt CO2e Scope 1+2 market-based GHG, 1,355,943 mt CO2e Scope 3 GHG, 424,797 MWh energy with 190,154 MWh renewable, 526 ML water withdrawal, 6,230 mt nonhazardous & 3,742 mt hazardous waste in FY25); and (12) U.S. Pharmaceutical & Healthcare FRED Benchmarks & Core Financial Statements (DB).
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as 'more than 52%' or 'over 40%' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Data updated 2026-10-29.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

Consolidated Revenue Architecture, Base Business (Ex-Veklury) & Geographic Disaggregation

HIV Franchise — Treatment & Prevention (PrEP) Portfolio by Brand × Geography

Liver Disease Franchise (HCV, HBV/HDV, PBC) & Veklury (Remdesivir) by Brand × Geography

Oncology (Kite Cell Therapy & Trodelvy ADC) & Other Products Portfolio by Brand × Geography

Gross-to-Net (GTN) Deductions, Rebates & Chargebacks Rollforward & U.S. Wholesaler Concentration

R&D Cost Structure, Acquired IPR&D & Strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS)

GAAP vs. Non-GAAP Profitability Margins, Adjusted Earnings & Reconciliation Adjustments

Manufacturing Inventories by Stage, PP&E by Geography, Drug Intangible Assets & Leases

Contingent Consideration (Level 3), Litigation Reserves & Restructuring Programs

Debt Maturity Profile, Capital Return, Stock-Based Compensation & Income Taxes (DTA/DTL & UTB)

Human Capital, CEO Pay Ratio (DEF 14A), Workplace Safety & Environmental Sustainability (ESG)

Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB)